Concentration-effect relations of 5-hydroxypropafenone in normal subjects

Area of Science:

• Pharmacology
• Clinical Pharmacology
• Cardiovascular Research

Background:

• Propafenone is a Class IC antiarrhythmic drug.
• 5-hydroxypropafenone is a major active metabolite of propafenone.
• Understanding the pharmacologic activity of 5-hydroxypropafenone is crucial for explaining propafenone's therapeutic effects.

Purpose of the Study:

• To evaluate the pharmacologic activity of 5-hydroxypropafenone in healthy subjects.
• To assess electrocardiographic changes and blood pressure alterations after oral administration of 5-hydroxypropafenone.
• To correlate drug concentration with observed pharmacodynamic effects.

Main Methods:

• A placebo-controlled, double-blind crossover study was conducted in 6 healthy extensive metabolizers of debrisoquine.
• Subjects received a single oral dose of 300 mg of 5-hydroxypropafenone.
• Electrocardiographic parameters (PQ, QRS, QTc) and blood pressure were measured.
• A pharmacokinetic-pharmacodynamic model was applied to analyze concentration-effect relationships.

Main Results:

• 5-hydroxypropafenone was well-absorbed, with a terminal half-life of 506-963 minutes.
• Significant prolongations in PQ and QRS duration were observed in 5 out of 6 subjects.
• No significant changes in QTc interval, heart rate, or supine blood pressure were noted.
• A greater decrease in systolic blood pressure was observed in the upright position compared to placebo (p < 0.05).

Conclusions:

• 5-hydroxypropafenone exhibits significant pharmacologic activity in humans.
• The observed QRS prolongation suggests a contribution to the antiarrhythmic effect of propafenone.
• These findings support the role of 5-hydroxypropafenone in the overall therapeutic activity of propafenone.